Post-Marketing Safety Study of Ramucirumab Plus FOLFIRI: Analysis of Age and Initial Dose of Irinotecan in Patients with Metastatic Colorectal Cancer

BACKGROUND: There is limited real-world evidence regarding the safety of ramucirumab plus FOLFIRI in patients with metastatic colorectal cancer (mCRC). OBJECTIVE: We evaluated the safety of ramucirumab plus FOLFIRI in patients with mCRC by age and initial dose of irinotecan. PATIENTS AND METHODS: Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Masuishi, Toshiki, Nagaoka, Soshi, Jin, Long, Yoshizawa, Kenichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491555/
https://www.ncbi.nlm.nih.gov/pubmed/37103777
http://dx.doi.org/10.1007/s40801-023-00366-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491555/
https://www.ncbi.nlm.nih.gov/pubmed/37103777
http://dx.doi.org/10.1007/s40801-023-00366-2

Ejemplares similares